Gastrointestinal Cancer

Comprehensive insight on later-line immunotherapy and combination strategies available for patients with advanced hepatocellular carcinoma.

Expert panelists consider which therapy they would use following failure of atezolizumab + bevacizumab in advanced hepatocellular carcinoma.

At the start of his career, Weijing Sun, MD, FACP, was motivated to explore potential new treatments for gastrointestinal malignancies, and is now an internationally known GI cancer expert.

The dual immunotherapy combination comprised of nivolumab given at 1 mg/kg and ipilimumab given at 3 mg/kg provided durable responses and long-term survival benefit in patients with advanced hepatocellular carcinoma following treatment with sorafenib.

Aiwu Ruth He, MD, PhD, discusses next steps for durvalumab in combination with gemcitabine plus cisplatin in patients with advanced biliary tract cancer.

Recent data highlight the value of the newly approved indications for nivolumab plus ipilimumab and nivolumab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma.

Pembrolizumab monotherapy continued to demonstrate durable antitumor activity with promising overall survival in patients with advanced hepatocellular carcinoma who received prior treatment with sorafenib, according to updated data from cohort 1 of the phase 2 KEYNOTE-224 trial.

After HER2 was established as an actionable target in gastric cancer, its amplification has become a key biomarker of interest for other gastrointestinal cancers.

Anne M. Noonan, MBBCh, discusses prominent new therapies in hepatocellular carcinoma, the benefits of immunotherapy in gastric cancer, chemotherapy developments in pancreatic cancer, and the importance of considering HER2-targeted therapy in metastatic colorectal cancer.

Dr Katz discusses the implications of a recently published phase 2 study investigating neoadjuvant mFOLFIRINOX with or without hypofractionated radiation therapy results for patients with borderline resectable pancreatic ductal adenocarcinoma.

Andrew H. Ko, MD, discusses the multitude of treatment options for patients with gastroesophageal cancer, emerging combinations in hepatocellular carcinoma, and how HER2 expression can drive therapy decisions in colorectal cancer.

Matthew H. G. Katz, MD, CMQ, FACS, FASCO, discusses the use of neoadjuvant mFOLFIRINOX in patients with borderline resectable pancreatic cancer.

Shared insight on which factors help to inform selection of second-line therapy for patients with advanced HCC following lenvatinib failure.

Centering discussion on a patient with advanced HCC, expert oncologists consider which agents they would use in the second line following lenvatinib failure.

First-line treatment with tislelizumab was found to result in a noninferior overall survival benefit to that achieved with sorafenib in adult patients with unresectable hepatocellular carcinoma, meeting the primary end point of the phase 3 RATIONALE 301 trial.

The addition of pembrolizumab to lenvatinib did not significantly improve overall survival or progression-free survival over lenvatinib alone when used in the frontline treatment of patients with unresectable hepatocellular carcinoma, missing the dual primary end points of the phase 3 LEAP-002 trial.

Tanios S. Bekaii-Saab, MD shares his perspective on exciting breakthroughs in GI malignancy research and treatment, focusing on HER2, BRAF V600E, and KRAS g12c.

Subject matter expert discusses the impetus for and data from the MOUNTAINEER trial, touching on patient populations, study design, and key efficacy and safety endpoints.

Dr. Bekaii-Saab shares the approach his practice takes to essential biomarker testing and next-generation sequencing in order to improve patient outcomes.

An experienced oncologist discusses the role of HER2 in GI malignancies and the applicability of the existing body of research concerning HER2 in breast cancer.

Before closing out their discussion on frontline therapy for advanced HCC, expert panelists review other novel combinations under investigation.

Tanios S. Bekaii-Saab, MD describes recent progress in the metastatic colorectal cancer treatment landscape and raises key questions concerning the future of the field.

Comprehensive insight on the selection and use of frontline tyrosine kinase inhibitors for patients with advanced hepatocellular carcinoma.

Neoadjuvant mFOLFIRINOX induced favorable overall survival results for patients with borderline resectable pancreatic ductal adenocarcinoma when administered prior to pancreatectomy, though neoadjuvant mFOLFIRINOX followed by hypofractionated radiation therapy did not prove to be similarly effective.

Expert panelists briefly review how a patient’s hepatitis status may influence treatment selection for advanced hepatocellular carcinoma.